Motif Bio PLC Grant of Options (9951V)

TIDMMTFB

RNS Number : 9951V

Motif Bio PLC

22 April 2016

Motif Bio plc

("Motif Bio" or the "Company")

Grant of share options to senior management

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has granted a total of 3,261,577 options to purchase ordinary shares of 1 pence each of Motif Bio ("Ordinary Shares").

Pete A. Meyers, Chief Financial Officer, has been granted 2,961,577 options to purchase Ordinary Shares which vest over a four year period and are partially based on meeting certain performance targets. Rajesh B. Shukla Ph.D., Vice President of Clinical Operations, was granted 300,000 options to purchase Ordinary Shares which vest over a four year period. The options have an exercise price of 40.50 pence per Ordinary Share, being the closing price of the Ordinary Shares on 21 April 2016, the date of grant of the options.

For further information please contact:

 
 Motif Bio plc                                                      info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
 Zeus Capital Limited (NOMAD & 
  BROKER) 
  Phil Walker/Dan Bate 
  Dominic Wilson                                                  +44 (0)20 3829 5000 
 Northland Capital Partners Limited 
  (BROKER) 
  Patrick Claridge/ David Hignell 
  John Howes/ Rob Rees (Broking)                                  +44 (0)20 7382 1100 
 Walbrook PR Ltd. (FINANCIAL PR        +44 (0)20 7933 8780 or motifbio@walbrookpr.com 
  & IR)                                                      Mob: +44 (0)7980 541 893 
  Paul McManus                                               Mob: +44 (0)7900 608 002 
  Mike Wort 
 
 MC Services AG (EUROPEAN IR) 
 Raimund Gabriel                                                   +49 (0)89 210 2280

Notes to Editors:

Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEAELFAESKEAF

(END) Dow Jones Newswires

April 22, 2016 02:00 ET (06:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024